Rabbit polyclonal phospho-specific antibodies against MARK2 S456, S569, S619, and MST2 S15 were generated and purified by AbMart, Inc. The peptides used for immunizing rabbits were AKVPA-pS-PLPGL (MAR2 S456), RVPVA-pS-PSAHN (MARK2 S569), GVTPA-pS-PSGHS (MARK2 S619), and KLKKL-pS-EDSLT (MST2 S15). The corresponding non-phosphorylated peptides were also used for antibody purification and blocking assays. Anti-MARK2, Cyclin B1, β-actin were purchased from Santa Cruz Biotechnology. Anti-MARK1, MARK3, MARK4, p-MARK T208 (activation loop), HDAC1, HDAC2, HDAC4, HDAC5, HDAC6, HDAC7, p-HDAC4/5/7(S246/S259/S155), p-HDAC4/5/7(S632/S661/S486), cleaved-PARP (human specific), cleaved-PARP (rodent specific), cleaved-caspase 3, Erk1/2, Zyxin, Survivin, p-YAP S127, p-YAP S397, YAP, and p-Aurora-A/B/C were from Cell Signaling Technology. Anti-GST and LATS2 antibodies were from Bethyl Laboratory. Anti-Aurora-A and Flag antibodies were from Sigma. Anti-α-tubulin antibody was from Abcam Inc. All other antibodies used in this study are listed in Table S1.
Zeng Y., Yin L., Zhou J., Zeng R., Xiao Y., Black A.R., Hu T., Singh P.K., Yin F., Batra S.K., Yu F., Chen Y, & Dong J. (2022). MARK2 Regulates Chemotherapeutic Responses through Class IIa HDAC-YAP Axis in Pancreatic Cancer. Oncogene, 41(31), 3859-3875.
+ Open protocol